- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04609670
Study of Radiolabeled ALXN2050 in Healthy Adult Males
January 23, 2023 updated by: Alexion Pharmaceuticals
A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C]-ALXN2050 in Healthy Adult Male Subjects
This is an open-label study to assess the absorption, metabolism, excretion, and mass balance of a single oral dose of carbon-14 ([14C])-ALXN2050 in healthy adult males.
Study Overview
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Clinical Trial Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- No clinically significant medical history, physical or neurological examination findings, screening clinical laboratory profiles, or electrocardiogram findings.
- Body mass index in the range of 18.0 to 32.0 kilograms (kg)/meter squared, inclusive, with a minimum body weight of 50.0 kg at screening.
- Non-sterile participants must agree to abstinence or use a highly effective method of contraception.
Exclusion Criteria:
- History of any medical or psychiatric condition or disease that might limit the participant's ability to complete or participate in this clinical study, confound the results of the study, or pose an additional risk to the participant by their participation in the study.
- History or presence of drug or alcohol abuse within previous 2 years, current user of tobacco/any nicotine-containing product, or positive drugs-of-abuse screen or alcohol screen at screening or Day -1 of Period 1.
- History or presence of seizures, head injury, or head trauma.
- History of procedures that could alter absorption or excretion of orally administered drugs.
- History of meningococcal infection, or has a first-degree relative with a history of meningococcal infection.
- Body temperature ≥ 38.0°Celcius at screening or check-in.
- Donation of whole blood from 3 months prior to first dosing or of plasma from 30 days before first dosing, or receipt of blood products within 6 months prior to first dosing.
- Has less than 1 bowel movement every 2 days or has a recent history of abnormal bowel movements, such as diarrhea, loose stools, or constipation, within 2 weeks prior to dosing.
- Has received radiolabeled substances or has been exposed to radiation sources within 12 months of dosing or is likely to receive radiation exposure or radioisotopes within 12 months of dosing such that participation in this study would increase their total exposure beyond the recommended levels considered safe.
- Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives (if known) or 30 days prior to dosing, whichever is longer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C]-ALXN2050
Participants will receive [14C]-ALXN2050.
|
A single dose of 200 milligrams (~85 microcuries) [14C]-ALXN2050 will be administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mass Balance Recovery In Urine And Feces After a Single Oral Dose Of [14C]-ALXN2050
Time Frame: Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
Mass balance will be assessed by evaluating total radioactivity recovery and the percent of the radioactive dose excreted in the urine and feces.
Mass balance will be calculated as a sum of the percent of the total radioactivity recovered in urine and feces plus any radioactivity dose lost due to emesis (if any occurred) relative to the administered radioactivity dose.
|
Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
Plasma Pharmacokinetics (PK) Of Total Radioactivity After A Single Oral Dose Of [14C]-ALXN2050: Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf)
Time Frame: Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
|
Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-ALXN2050: Area Under The Concentration Versus Time Curve, From Time 0 To The Time Of The Last Measurable Concentration (AUC0-last)
Time Frame: Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
|
Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-ALXN2050: Maximum Observed Plasma Concentration (Cmax)
Time Frame: Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
|
Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-ALXN2050: Time To Maximum Observed Plasma Concentration (Tmax)
Time Frame: Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
|
Plasma PK Of ALXN2050 After A Single Oral Dose Of [14C]-ALXN2050: AUC0-inf
Time Frame: Up to 168 hours postdose
|
Up to 168 hours postdose
|
|
Plasma PK Of ALXN2050 After A Single Oral Dose Of [14C]-ALXN2050: AUC0-last
Time Frame: Up to 168 hours postdose
|
Up to 168 hours postdose
|
|
Plasma PK Of ALXN2050 After A Single Oral Dose Of [14C]-ALXN2050: Cmax
Time Frame: Up to 168 hours postdose
|
Up to 168 hours postdose
|
|
Plasma PK Of ALXN2050 After A Single Oral Dose Of [14C]-ALXN2050: Tmax
Time Frame: Up to 168 hours postdose
|
Up to 168 hours postdose
|
|
Percentage Of Total Radioactivity Detected For Each ALXN2050 Metabolite in Plasma, Urine, And Feces
Time Frame: Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
ALXN2050 metabolic profiling in plasma, urine, and feces will be performed in samples containing sufficient amounts of radioactivity.
The percent of dose represented by each of the metabolites will be calculated using the radioactivity concentration equivalent data combined with the metabolic profiling data.
The percentage of each identified metabolite to total radioactivity in plasma will be estimated based on plasma metabolic profiling data.
|
Up to 168 hours postdose or maximum of 504 hours for extended collection period postdose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number Of Participants Receiving A Single Oral Administration Of [14C]-ALXN2050 With Treatment-emergent Adverse Events
Time Frame: Day 1 (after dosing) through follow-up (30 [+/- 2] days after dosing on Day 1
|
Day 1 (after dosing) through follow-up (30 [+/- 2] days after dosing on Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 12, 2021
Primary Completion (Actual)
August 23, 2021
Study Completion (Actual)
August 23, 2021
Study Registration Dates
First Submitted
October 26, 2020
First Submitted That Met QC Criteria
October 26, 2020
First Posted (Actual)
October 30, 2020
Study Record Updates
Last Update Posted (Actual)
January 25, 2023
Last Update Submitted That Met QC Criteria
January 23, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ALXN2050-HV-106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on [14C]-ALXN2050
-
AlexionRecruiting
-
AlexionCompleted
-
Alexion Pharmaceuticals, Inc.Active, not recruitingGeneralized Myasthenia Gravis | Myasthenia GravisUnited States, Spain, Korea, Republic of, Canada, Germany, Italy, Serbia, Taiwan
-
AlexionActive, not recruitingParoxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
-
AlexionRecruitingHealthy | Impaired Hepatic FunctionUnited States
-
Alexion PharmaceuticalsCompleted
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompleted
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Arcus Biosciences, Inc.Gilead SciencesCompleted
-
BiogenDenali Therapeutics Inc.Completed